文献速递眼底病与葡萄膜炎青光眼

抗C1q抗体片段ANX007玻璃体内给药后在非人灵长类中的药代动力学及靶点结合指标

Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

该非临床研究在食蟹猴中评估了抗C1q抗体片段ANX007经玻璃体内给药后的生物分布与C1q靶点结合情况。单次双侧给药1或5 mg/眼后,游离药物在玻璃体中可检测至4周,半衰期约3天;重复给药5 mg/眼后,灌注视网膜和脉络膜中游离ANX007可检测至末次给药后4周,视神经中约2周。C1q靶点结合与游离药物水平强相关,数据支持ANX007进一步临床评估。

要点

  • 单次玻璃体内注射ANX007 1或5 mg/眼后,玻璃体游离药物可检测至4周,半衰期约3天。
  • 重复给药5 mg/眼后,灌注视网膜和脉络膜中游离ANX007可检测至末次给药后4周,视神经中约2周。
  • 房水、玻璃体和视网膜组织中C1q靶点结合与游离药物水平强相关。

核心结论

  • 玻璃体内给药后,ANX007分布至视网膜中与神经退行性眼病相关的部位,并有明确的C1q靶点结合证据。
  • 基于其抑制C1q及下游活性的作用机制,预测ANX007可减轻视网膜中经典补体激活驱动的组织损伤。
  • 这些数据支持ANX007的进一步临床评估。

研究设计与样本

  • 非临床研究:雌性幼年食蟹猴(n=12)单次双侧玻璃体内注射1或5 mg ANX007/眼,约4周后采集玻璃体及非灌注组织样本。
  • 另一项研究中,雄性(n=6/5)和雌性(n=6/5)动物在第1天和第29天重复双侧给药1、2.5或5 mg ANX007/眼,第44天或第59天采集房水和玻璃体。
  • 5 mg/眼重复给药组组织经灌注,末次给药后约2周和4周采集视网膜、脉络膜和视神经样本。

主要发现

  • 单次给药1和5 mg剂量水平下,玻璃体游离药物可检测至4周,半衰期约3天。
  • 重复给药5 mg/眼后,灌注视网膜和脉络膜中游离ANX007可检测至末次给药后4周,视神经中可检测至末次给药后约2周。
  • 房水、玻璃体和视网膜组织中C1q靶点结合与游离药物水平呈强相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: C1q and the classical complement cascade are key regulators of synaptic pruning, and their aberrant activation has been implicated in neurodegenerative ophthalmic diseases including geographic atrophy and glaucoma. The antigen-binding fragment antibody ANX007 specifically recognizes globular head groups of C1q to block substrate binding and functionally inhibit classical complement cascade activation. ANX007 was assessed in nonclinical studies of biodistribution and C1q target engagement in the eye following intravitreal (IVT) administration in cynomolgus monkeys. METHODS: Female juvenile cynomolgus monkeys (n = 12) received a single bilateral dose of 1 or 5 mg ANX007/eye, with vitreous and non-perfused tissue samples collected approximately 4 weeks later. In a separate study, male (n = 6/5) and female (n = 6/5) animals received repeat bilateral dosing of 1, 2.5, or 5 mg ANX007/eye on days 1 and 29, with aqueous and vitreous collections on day 44 or day 59. Tissues from the 5 mg/eye repeat-dose group were perfused, and retina, choroid, and optic nerve samples were collected approximately 2 and 4 weeks post-last dose. RESULTS: Following a single dose of ANX007, vitreous levels of free drug were measurable through 4 weeks at both the 1 and 5 mg dose levels, with approximately 3-day half-life. With repeat dose of 5 mg/eye, free-ANX007 was measurable 4 weeks post-last dose in perfused retina and choroid and up to approximately 2 weeks post-last dose in optic nerve. There was a strong correlation between C1q target engagement and free drug levels in aqueous and vitreous humors and retinal tissue. CONCLUSIONS: Following IVT administration, ANX007 distributes to sites within the retina that are relevant to neurodegenerative ophthalmic disease with clear evidence of C1q target engagement. Based on its mechanism of action inhibiting C1q and its downstream activity, ANX007 is predicted to mitigate tissue damage driven by classical complement activation in the retina. These data support further clinical evaluation of ANX007.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Grover A, Sankaranarayanan S, Mathur V, et al. Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates. Invest Ophthalmol Vis Sci. 2023. PMID: 36729444. doi:10.1167/iovs.64.2.3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。